Oncomed Pharma (OMED) Misses Q4 EPS by 30c; Names New CFO
Tweet Send to a Friend
Oncomed Pharma (NASDAQ: OMED) reported Q4 EPS of ($0.15), $0.30 worse than the analyst estimate of $0.15. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
